This raises the possibility that therapeutic elevation of the oxidoreductase activity of PDI, either by increasing the cellular levels of PDI or by administration of small molecular mimics of PDI activity, may have potential for the treatment of ALS and related neurodegenerative disorders associated with protein misfolding. This evidence concerns the gene P4HB and amyotrophic lateral sclerosis.